Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.
Dhainaut JF, et al. Among authors: vincent jl.
Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24.
Intensive Care Med. 2003.
PMID: 12712239
Clinical Trial.